Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by C10H12N2on Jan 28, 2022 10:41pm

277 Views

Post# 34373854

If Algernon can run the table with DMT Salt Patents -

The DMT Salt patents alone could ultimately be worth BILLION$

Does anybody know if ANY of the other Psychedelic companies have come up with such an approach for their drug portfolio? My guess is all the other psychedelic companies have taken notice. They are now likely racing to come up with their own SALT versions of X Y Z drugs. There was some genius brainpower attached to the DMT SALT patent(s). Just like it was a genius idea to go in a completely different direction than all the other psychedelic compaines out there looking to treat various mood disorders. Algernon's time in the sun is coming sooner rather than later.

Meanwhile, let the Doomsday Preppers continue their rein of igno-rants.